Eikon Therapeutics, Inc.

Listed Company
EIKNCIK 0001861123NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Business

Eikon Therapeutics is a late-stage clinical biopharmaceutical company developing innovative oncology medicines by integrating advanced engineering with biology research. The company's pipeline includes EIK1001 (TLR 7/8 dual-agonist in Phase 2/3 trials for melanoma and NSCLC), EIK1003 & EIK1004 (selective PARP1 inhibitors in Phase 1/2 trials), EIK1005 (WRN helicase inhibitor in Phase 1/2 trials), and EIK1006 (AR antagonist in preclinical development). Eikon operates globally with clinical trial sites across North America, Europe, Asia-Pacific, and other regions, leveraging its proprietary single-molecule tracking platform to discover and optimize drug candidates.

Summary from 10-K filed 2026-07-01

Financials

Financial data not availableNo XBRL filings found for this entity.

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Eikon Therapeutics, Inc.'s CIK number?

Eikon Therapeutics, Inc.'s SEC CIK number is 0001861123 (1861123). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Eikon Therapeutics, Inc.'s SEC filings?

All of Eikon Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Eikon Therapeutics, Inc. last report earnings?

Eikon Therapeutics, Inc. (EIKN) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216744). This is Eikon Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Eikon Therapeutics, Inc.'s most recent earnings 8-K?

Eikon Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216744. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Eikon Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →